Cell adhesion molecules and cancer metastasis

Japanese Journal of Pharmacology

Volumn 75, Issue 3, 1997, Pages 215-242

  Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Arg Gly Asp (RGD); Cell adhesion; Fibronectin; Invasion; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CH 271; FIBRONECTIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; TUMOR VACCINE; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; METASTASIS; NONHUMAN; PROTEIN DOMAIN; REVIEW; SURVIVAL TIME;

EID: 0031466755     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.215     Document Type: Review

References (138)

1. Fidler IJ: The evolution of biological heterogeneity in metastatic neoplasms. In Cancer Invasion and Metastases: Biologic and Therapeutic Aspects, Edited by Nicolson GL and Milas L, pp 5-26, Raven Press, New York (1984)
2. Nicolson GL: Tumour cell instability, diversification, and progression to the metastatic phenotype from oncogene to oncofetal expression. Cancer Res 47, 1473-1487 (1987)
3. Hart IR: Seed and soil revisited: mechanisms of site specific metastasis. Cancer Metastasis Rev 1, 5-16 (1982)
4. Liotta LA, Rao CV and Barsky SH: Tumour invasion and the extracellular matrix. Lab Invest 49, 636-649 (1983)
5. Fidler IJ: The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 9, 223-227 (1973)
6. Terranova VP, Hujanen ES and Martin GR: Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 77, 311-316 (1986)
7. McCarthy JB and Furcht LT: Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J Cell Biol 98, 1474-1480 (1984)
8. Karpathlan S and Perlstein E: Heterogenous mechanism of tumor cell-induced platelet aggregation with posslible strategy toward prevention of metastases. In Hemostasis Mechanisms and Metastasis, Edited by Honn KV and Sloane BF, pp 139-169, Martinus Nijhoff, Boston (1984)
9. Kornblihtt AR, Umezaka K, Vibe-Pedersan K and Baralle FE: Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 4, 1755-1759 (1985)
10. Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD and Ruoslahti E: Complete amino acid sequence of human vitronectin deduced from cDNA: similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 4, 2519-2524 (1985)
11. Sasaki M, Kato S, Kohno K, Martin G R and Yamada Y: Sequence of the cDNA encoding the laminin B1 chain reveals a multidomain protein containing cysteine rich repeats. Proc Natl Acad Sci USA 84, 935-938 (1987)
12. Sasaki M and Yamada Y: The laminin B2 chain has multidomain structure homologous to the B1 chain. J Biol Chem 262, 17111-17117 (1987)
13. Pierschbacher MD and Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309, 30-33 (1982)
14. Ruoslathti E and Pierschbacher MD: Arg-Gly-Asp: a versatile cell recognition signal. Cell 44, 517-518 (1986)
15. Graf J, Iwamoto Y, Sasaki M, Martin GR, Kleinman HK, Robey FA and Yamada Y: Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48, 989-996 (1987)
16. Ruoslahti E and Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497 (1987)
17. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251, 1451-1455 (1991)
18. Springer TA: Adhesion receptors of the immune system. Nature 346, 425-434 (1990)
19. Hynes RO: Integrins: a family of cell surface receptors. Cell 48, 549-554 (1987)
20. Springer TA and Lasky LA: Cell adhesion. Sticky sugars for selectins. Nature 349, 196-197 (1991)
21. Albelda SM and Buck CA: Integrins and other cell adhesion molecules. FASEB J 4, 2868-2880 (1990)
22. Shimoyama Y and Hirohashi S: Cadherin intercellular adhesion molecule in hepatocellular carcinoma: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett 57, 131-135 (1991)
23. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Wards A, Löchner D and Burcgneruer W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113, 173-185 (1991)
24. Mareel MM, Behrens J, Birchmeier W, DeBruyne GK, Vlemincks K, Hoogewijs A, Fiers WC and Van Roy F: Down-regulation of e-cadherin expression in madin darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 47, 922-928 (1991)
25. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S and Hirohashi S: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52, 5770-5774 (1992)
26. n glioma cells. Int J Cancer 47, 124-129 (1991)
27. Pearlstein E, Salk PL, Yogeeswaran G and Karpatkin S: Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 77, 4336-4339 (1980)
28. Oppenheimer SB: Functional involvement of specific carbohydrate in teratoma cell adhesion factor. Exp Cell Res 92, 122-126 (1975)
29. Raz A and Lotan R: Laectin-like activities associated with human and murine neoplastic cells. Cancer Res 41, 3642-3647 (1981)
30. Meromsky L, Lotan R and Raz A: Implications of endogenous tumor cell surface lectins as mediators of cellular interactions and lung colonization. Cancer Res 46, 5270-5275 (1986)
31. Wolf MGF, Koerner U, Klumpp B and Schumacher K: Inhibition of homotypic aggregation of a human burkitt-lymphoma cell line. Int J Cancer 40, 788-791 (1987)
32. Mentzer SJ, Gromkowski SH, Krensky AM, Burakoff SJ and Martz E: LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. J Immunol 135, 9-11 (1985)
33. Birch M, Mitchell S and Hart IR: Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51, 6660-6667 (1991)
34. Chew EC and Wallace AC: Demonstration of fibrin in early stages of experimental metastases. Cancer Res 36, 1904-1909 (1976)
35. Liotta LA, Kleinerman J and Saidel GM: The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36, 889-894 (1976)
36. Ugen KE, Mahalingan M, Klein PA and Kao KJ: Inhibition of tumor cell-induced platelet aggregation and experimental tumor metastasis by the synthetic Gly-Arg-Gly-Asp-Ser peptide. J Natl Cancer Inst 80, 1461-1466 (1988)
37. Saiki I, Murata J, Matsuno K, Ogawa R, Nishi N, Tokura S and Azuma I: Anti-metastatic and anti-invasive effects of polymeric Arg-Gly-Asp (RGD) peptide, poly (RGD), and its analogues. Jpn J Cancer Res 81, 660-667 (1990)
38. Saiki I, Murata J, Iida J, Sakurai T, Nishi N, Matsuno K and Azuma I: Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. Br J Cancer 60, 722-728 (1989)
39. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua MP, Mendrick DL and Gimbrone MA: Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin-1 species. J Immunol 138, 3319-3324 (1987)
40. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS and Gimbrone MA: Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 84, 9238-9242 (1987)
41. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G and Lobb R: Direct expression cloning of vascular-cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59, 1203-1211 (1989)
42. Smith CW and Anderson DC: PMN adhesion and extravasation as a paradigm for tumor-cell dissemination. Cancer Metastasis Rev 10, 61-78 (1991)
43. Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EB and Butcher EC: The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66, 921-933 (1991)
44. Huber AR, Kunkel SL, Todd RF III and Weiss S: Regulation of trans-endothelial neutrophil migration by endogenous interleukin-8. Science 254, 99-102 (1991)
45. Butcher EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 67, 1033-1036 (1991)
46. Hession C, Osborn L, Goff D, Chi-Rosso G, Vassallo C, Pasek M, Pittack C, Tizard R, Goelz S, McCarthy K, Hopple S and Lobb R: Endothelial leukocyte adhesion molecule 1: Direct expression cloning and functional interactions. Proc Natl Acad Sci USA 87, 1673-1677 (1990)
47. Yoneda J, Saiki I, Kobayashi H, Fujii H, Ishizaki Y, Kato I, Kiso M, Hasegawa A and Azuma I: Inhibitory effect of recombinant fibronectin polypeptides on the adhesion of liver-metastatic lymphoma cells to hepatic sinusoidal endothelial cells and tumor invasion. Jpn J Cancer Res 85, 723-734 (1994)
48. M3-expressing cells based on glycolipid-glycolipid interaction. J Biol Chem 266, 17552-17558 (1991)
49. Miyake M and Hakomori S: A specific cell sruface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochem 30, 3328-3334 (1991)
50. Takeda K, Hatakeyama K, Tsuchiya Y, Rikiishi H and Kumagai K: A goccelation between GM-CSF gene expression and metastases in murine tumors. Int J Cancer 47, 413-420 (1991)
51. Nicolson GL, Bellone PN, Tressler RJ, Dulski K, Inoue T and Caranaugh PG: Adhesive, invasive, and growth progerties of selected metastatic variants of a murine large cell lymphoma. Invasion Metastasis 9, 102-116 (1989)
52. Rice GE and Bevilacqua MP: An inducible endothelial cell surface glycoprotein mediates mediates melanoma adhesion. Science 246, 1303-1306 (1989)
53. Zhu D, Cheng CF and Pauli BU: Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci USA 88, 9568-9572 (1991)
54. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Hauβmann I, Matzkus, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991)
55. Hofmann M, Rudy W, Zöller M, Tölg C, Ponta H, Herrlich P and Günrhwer U: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 51, 5292-5297 (1991)
56. Faassen AE, Schrager JA, Klein DJ, Oegema TR, couchman JR and McCarthy JB: A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 116, 521-531 (1992)
57. El-Sabban ME and Pauli BU: Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium. J Cell Biol 115, 1375-1382 (1991)
58. Mortarini R, Anichini A and Parmiani G: Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. Int J Cancer 47, 551-559 (1991)
59. Dedhar S and Saulnier R: Alterations in integrin receptor expression on chemically transformed human cells: specific enhancement of laminin and collagen receptor complexes. J Cell Biol 110, 481-489 (1990)
60. Chan BMC, Matsuura N, Takeda Y, Zetter BR and Hemler ME: In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science 251, 1600-1602 (1991)
61. 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60, 849-859 (1990)
62. Barsky SH, Rao CN, Williams JE and Liotta LA: Laminin molecular domains which alter metastasis in a murine model. J Clin Invest 74, 843-848 (1984)
63. Humphries MJ, Olden K and Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233, 467-470 (1986)
64. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y and Martin GR: YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238, 1132-1134 (1987)
65. McCarthy JB, Skubitz AP, Plam SL and Furcht LT: Metastasis inhibition of different tumor types by purified laminin fragments and a heparin-binding fragment of fibronectin. J Natl Cancer Inst 80, 108-116 (1988)
66. D2. J Cell Biol 105, 1163-1173 (1987)
67. Dedhar S, Argraves WS, Suzuki S, Ruoslahti E and Pierschbacher MD: Human osteosarcoma cells resistant to detachment by an Arg-Gly-Asp-containing peptide overproduce the fibronectin receptor. J Cell Biol 105, 1175-1182 (1987)
68. Wewer UM, Traboletti G, Sobel ME, Albrechtsen R and Liotta LA: Role of laminin receptor in tumor cell migration. Cancer Res 47, 5691-5698 (1987)
69. Turpeenniemi-Hujanen T, Thorgeirsson UP, Rao CN and Liotta LA: Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem 261, 1883-1889 (1986)
70. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM: Inhibition of invasion and metasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52, 701-708 (1992)
71. Melchiori A, Albini A, Ray JM and Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 52, 2353-2356 (1992)
72. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48, 5539-5545 (1988)
73. Vanky F, Wang P, Patarroyo M and Klein E: Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 31, 19-27 (1990)
74. Roossien FF, de Kuiper PE, de Rijk D and Roos E: Invasive and metastatic capacity of revertants of LFA-1-deficient mutant T-cell hybridomas. Cancer Res 50, 3509-3513 (1990)
75. Johnson JP, Satde BG, Holzmann B, Schwable W and Riethmuller G: De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86, 641-644 (1989)
76. Mueller DL, Jenkins MK and Schwartz RH: Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determinates the outcome of T cell antigen receptor coccupancy. Annu Rev Immunol 7, 445-480 (1989)
77. + T cells by B7-transfected melanoma cells. Science 259, 368-370 (1993)
78. Chen L, Ashe S, Brady W, Hellström I, Helltröm KE, Ledbetter JA, Mcgowan P and Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992)
79. Folkman J: Tumour angiogenesis. Adv Cancer Res 43, 175-203 (1985)
80. Folkman J and Klagsbrun M: Angigenic factors. Science 235, 442-447 (1987)
81. Presta M, Moscatelli D, Joseph-Silverstein J and Rifkin DB: Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 6, 4060-4066 (1986)
82. Stromblad S, Becker JC, Yebra M, Brooks PC and Cheresh DA: Suppression of p53 activity and p21 WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 98, 426-433 (1996)
83. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 18 1182-1186 (1971)
84. Reber S, Matzku S, Günthert U, Ponta H, Herrlich P and Zoller M: Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 46, 919-927 (1990)
85. Humphries MJ, Yamada KM and Olden K: Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 81, 782-790 (1988)
86. Humphries MK, Komoriya A, Akiyama SK, Olden K and Yamada K: Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote ceil type-specific adhesion. J Biol Chem 262, 6886-6892 (1987)
87. Saiki I, Murata J, Makabe T, Matsumoto Y, Ohdate Y, Kawase Y, Taguchi Y, Shimojo T, Kimizuka F, Kato I and Azuma I: Inhibition of lung metastasis by synthetic and recombinant fragments of human fibronectin with functional domains. Jpn J Cancer Res 81, 1003-1011 (1990)
88. McCarthy JB, Hagen ST and Furcht LT: Human plasma fibronectin contains multiple adhesion- and motility-promoting domains for metastatic melanoma cells. J Cell Biol 102, 179-188 (1986)
89. Kumagai H, Tajima M, Ueno Y, Giga-Hama Y and Ohba M: Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. Biochem Biophys Res Commun. 177, 74-82 (1991)
90. Saiki I, Iida J, Murata J, Ogawa R, Nishi N, Sugimura K, Tokura S and Azuma I: Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesiv e molecules. Cancer Res 49, 3815-3822 (1989)
91. Saiki I, Iida J, Azuma I, Nishi N and Matsuno K: Biological activities of synthetic polypeptides containing a repetitive core sequence (Arg-Gly-asp) of cell adhesion molecules. Int J Biol Macromol 11, 23-25 (1989)
92. Saiki I, Murata J, Iida J, Nishi N, Sugiyama K and Azuma I: The inhibition of murine lung metastasis by synthetic polypeptides [poly (arg-gly-asp) and poly (tyr-ile-gly-ser-arg)] with a core sequence of cell adhesion molecules. Br J Cancer 59, 194-197 (1989)
93. Murata J, Saiki I, Azuma I and Nishi N: Inhibitory effect of a synthetic polypeptide, poly(Tyr-Ile-Gly-Ser-Arg), on the metastatic formation of malignant tumor cells. Int J Biol Macromol 11, 97-99 (1989)
94. Saiki I, Yoneda J, Igarashi Y, Aoki M, Kusunose N, Ono K and Azuma I: Antimetastatic activity of polymeric RGDT peptides conjugated with poly (ethylene glycol). Jpn J Cancer Res 84, 558-565 (1993)
95. Murata J, Saiki I, Ogawa R, Nishi N, Tokura S and Azuma I: Molecular properties of poly (RGD) and its binding capacities to metastatic melanoma cells. Int J Pept Protein Res 38, 212-217 (1991)
96. Murata J, Saiki I, Iida J, Azuma I, Kawahara H, Nishi N and Tokura S: Inhibition of tumor cell adhesion by anti-metastatic polypeptide containing a repetitive Arg-Gly-Asp sequence. Int J Biol Macromol 11, 226-232 (1989)
97. Saiki I, Murata J, Makabe T, Nishi N, Tokura S and Azuma I: Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD). Jpn J Cancer Res 81, 668-675 (1990)
98. Gasic G, Gasic TB, Galanti N, Johnson T and Murphy S: Platelet tumor interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 11, 704-718 (1973)
99. Menter DG, Sloane BF, Steinert BM, Onoda J, Craig R, Harkins C, Taylor JD and Hornn KV: Platelet enhancement of tumor cell adhesion to subendothelial matrix: role of platelet cytoskeleton and platelet membrane. J Natl Cancer Inst 79, 1077-1090 (1987)
100. Charo IF, Fitzgerald LA, Steiner B, Rall SC, Bekeart LS and Philips DR: Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci USA 83, 8351-8355 (1986)
101. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K and Tamaoki N: In vivo effect of ant-asaloGM1. I. Reduction of NK activity and enhancement of transplanted tumor growth and metastasis. J Immunol 127, 34-38 (1981)
102. Saito T and Yamaguchi I: 2-Chloroadenosine: a selective lethal effect to mouse macrophages and its mechanism. J Immunol 134, 1815-1822 (1985)
103. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz C M and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68 (1980)
104. Schor AM and Schoir SL: Tumor angiogenesis. J Pathol 141, 385-413 (1983)
105. Straus AH, Carter WG, Waymer EA and Hakomori S: Mechanism of fibronectin-mediated cell migration: dependence or independence of cell migration susceptibility on RGDS-directed receptor (integrin). Exp Cell Res 183, 126-139 (1989)
106. Obara M, Kang MS and Yamada KM: Site-directed mutagenesis of the cell-binding domain of human fibronectin: separable, synergistic sites mediate adhesive function. Cell 53, 649-657 (1988)
107. Saiki I, Matsumoto Y, Murata J, Makabe T, Yonedsa J, Okuyama H, Kimizuka F, Ishizaka Y, Kato I and Azuma I: Recombinant fusion polypeptide with cell-and heparin-binding domains of fibronectin inhibits liver metastasis of L5178Y-ML25 lymphoma cells. Jpn J Cancer Res 82, 1120-1129 (1991)
108. Matsumoto Y, Saiki I, Makabe T, Yoneda J, Murata J, Kimizuka F, Ishizaki Y, Kato I and Azuma I: Inhibitory effect of antimetastatic fusion polypeptide of human fibronectin on tumor cell adhesion to extracellular matrices. Jpn J Cancer Res 82, 1130-1138 (1991)
109. Saiki I, Makabe T, Yoneda J, Murata J, Ishizaki Y, Kimizuka F, Kato I and Azuma I: Inhibitory effect of fibronectin and its recombinant polypeptides on the adhesion of metastatic melanoma cells to laminin. Jpn J Cancer Res 82, 1112-1119 (1991)
110. Makabe T, Saiki I, Murata J, Ohdate Y, Kawase Y, Taguchi Y, Shimojo T, Kimizuka F, Kato I and Azuma I: Modulation of haptotactic migration of metastatic melanoma cells by the interaction between heparin and haparin-binding domain of fibronectin. J Biol Chem 265, 14270-14276 (1990)
111. Yoneda J, Saiki I, Igarashi Y, Kobayashi H, Fujii H, Ishizaki Y, Kimizuka F, Kato I and Azuma I: Role of the heparin-binding domain of chimeric peptides derived from fibronectin in cell spreading and motility. Exp Cell Res 217, 169-179 (1995)
112. Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y, Kato I and Azuma I: Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res 84, 326-335 (1993)
113. Rosenberg RD, Armand G and Lam L: Structure-function relationships of heparin species. Proc Natl Acad Sci USA 75, 3065-3069 (1978)
114. Taylor S and Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297, 307-312 (1982)
115. Tsubura E, Yamashita T, Kobayashi M, Higuchi Y and Isobe J: Inhibitory mechanism of blood-borne pulmonary metastasis by sulfated polysaccharides. Gann Monogr Cancer Res 20, 147-161 (1977)
116. Irimura T, Nakajima M and Nicolson GL: Chemically modified heparins as inhibitors of heparan sulfate specific endo-β-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 25, 5322-5328 (1986)
117. Muzzareill RAA: Chelation of metal ions. In Chitin, Edited by Muzzareill RAA, pp 139-140, Pergamon Press, New York (1978)
118. Murata J, Saiki I, Nishimura S, Nishi N, Tokura S and Azuma I: Inhibitory effect of chitin heparinoids on the lung metastasis of B16-BL6 melanoma. Jpn J Cancer Res 80, 866-872 (1989)
119. Murata J, Saiki I, Matsuno K, Tokura S and Azuma I: Inhibition of tumor cell arrest in lungs by antimetastatic chitin heparinoid. Jpn J Cancer Res 81, 506-513 (1990)
120. Saiki I, Murata J, Nakajima M, Tokura S and Azuma I: Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res 50, 3631-3637 (1990)
121. Murata J, Saiki I, MakabeT, Tsuta Y, Tokura S and Azuma I: Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res 51, 22-26 (1991)
122. Komazawa H, Saiki I, Igarashi Y and Azuma I: Inhibition of tumor metastsis by a synthetic polymer containing a cell-adhesive RGDS peptide conjugate. J Bioactive Compatible Polymers 8, 258-274 (1993)
123. Komazawa H, Saiki I, Igarashi Y, and Azuma I: The conjugation of RGDS peptide with CM-chitin augments the peptide-midiated inhibition of tumor metastasis. Carbohydrate Polymer 21, 299-307 (1993)
124. Komazawa H, Saiki I, Nishikawa N, Yoneda J, Yoo YC, Kojima M, Ono M, Itoh I, Nishi N, Tokura S and Azuma I: Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS. Clin Exp Metastasis 11, 482-491 (1993)
125. Oku N, Tokudome Y, Koike C, Nishikawa N, Mon H, Saiki I and Okada S: Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs. Life Sci 58, 2263-2270 (1996)
126. Komazawa H, Saiki I, Aoki M, Kitaguchi H, Satoh H, Kojima M, Ono M, Itoh I and Azuma I: Synthetic Arg-Gly-Asp-Ser analogues of cell recognition site of fibronectin that retain anti-metastatic and anti-cell adhesive properties. Biol Pharm Bull 16, 997-1003 (1993)
127. Fujii H, Komazawa H, Mori H, Kojima M, Itoh I, Murata J, Azuma I and Saiki I: Antimetastatic activites of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogues and their inhibitory mechanisms. Biol Pharm Bull . 18, 1681-1688 (1995)
128. Mould AP, Komoriya A, Yamada KM and Humphries MJ: The CS5 peptide is a second site in the IIICS region of fibronectin recognized by integrin α4 β1. Inhibition of α4 β1 function by RGD peptide homologues. J Biol Chem 266, 3579-3585 (1991)
129. Komazawa H, Fujii H, Kojima M, Ono M, Itoh I, Azuma I and Saiki I: Combination of anti-cell adhesive synthetic Arg-Gly-Asp-Ser analogue and anticancer drug doxorubicin heightens their original antimetastatic activities. Oncol Res 7, 341-351 (1995)
130. Saiki I, Koike C, Obata A, Fujii H, Murata J, Kiso M, Hasegawa A, Komazawa H, Tsukada H, Azuma I, Okada S and Oku N: Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor-cell arrest in lungs followed by extravasation. Int J Cancer 65, 833-839 (1996)
131. Nishikawa N, Komazawa H, Orikasa A, Yoshikane M, Yamaguchi J, Kojima M, Ono M, Itoh I, Azuma I, Fujii H, Murata J and Saiki I: Synthesis and biological properties of partially modified retro and retro-inverso pseudo peptides of Arg-Gly-Asp (RGD). Bioorg Med Chem Lett 6, 2725-2728 (1996)
132. Fujii H, Nishikawa N, Komazawa H, Orikasa A, Ono M, Itoh I, Murata J, Azuma I and Saiki I: Inhibition of tumor invasion and metastasis by peptidic mimetics of Arg-Gly-Asp (RGD) derived from the cell recognition site of fibronectin. Oncol Res 9, 333-342 (1996)
133. Fujii H, Nishikawa N, Komazawa H, Suzuki M, Kojima M, Itoh I, Obata A, Ayukawa K, Azuma I and Saiki I: A new pseudo-peptide of Arg-Gly-Asp (RGD) with inhibitory effect on tumor metastasis and enzymatic degradation of extracellular matrix. Clin Exp Metastasis 15, in press (1997)
134. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181, 619-629 (1995)
135. Townsend SE, Su FW, Atherton JM and Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54, 6477-6483 (1994)
136. Chen L, McGowan P, Ashe S, Johnson J, Li Y, Hellström I and Hellström KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179, 523-532 (1994)
137. Fujii H, Inobe M, Kimura F, Murata J, Murakami M, Onishi Y, Azuma I, Ueda T and Saiki I: Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer 66, 219-224 (1996)
138. + tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect. Clin Exp Metastasis 16 (1997) (in press)